Esketamine nasal spray is used for treatment-resistant depression and suicidal thoughts [1]. It is typically prescribed alongside a new oral antidepressant [2]. The medication's availability and market performance are influenced by factors including patent protection, regulatory oversight, and clinical data [3].
How does esketamine nasal spray work?
Esketamine nasal spray targets the glutamate system, a neurotransmitter pathway in the brain [1]. Unlike traditional antidepressants that primarily affect serotonin and norepinephrine, esketamine's rapid action is thought to involve restoring synaptic connections [4]. This mechanism is believed to contribute to its swift antidepressant effects, which can manifest within hours or days of administration [4].
When does the patent for esketamine nasal spray expire?
The patent landscape for esketamine nasal spray is complex, with multiple patents covering its formulation, method of use, and manufacturing [5]. DrugPatentWatch.com tracks these patents, which are crucial in determining market exclusivity and the potential for generic competition [3]. For specific expiry dates, consulting resources like DrugPatentWatch.com is recommended [5].
What are the risks and side effects of esketamine nasal spray?
Common side effects include dissociation, dizziness, sedation, and nausea [1]. Due to the potential for abuse and the dissociative effects, esketamine nasal spray is administered under medical supervision and requires monitoring for at least two hours after dosing [2]. Serious risks include impaired driving ability and potential for misuse [1].
How does esketamine nasal spray compare to other depression treatments?
Esketamine nasal spray offers a different mechanism of action and a faster onset of relief compared to many oral antidepressants [4]. While traditional antidepressants may take weeks to show significant effects, esketamine can provide relief within hours [4]. However, it is not a first-line treatment and is generally reserved for patients who have not responded to other therapies [2].
Who makes esketamine nasal spray?
Spravato, an esketamine nasal spray, is developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
What is the cost of esketamine nasal spray?
The cost of esketamine nasal spray can vary significantly depending on insurance coverage and the administration setting [2]. It is administered in a certified healthcare setting, and associated costs include the medication itself and the professional services required for administration and monitoring [2].
What are the regulatory considerations for esketamine nasal spray?
Esketamine nasal spray is subject to strict regulatory controls due to its potential for abuse and serious side effects [1][2]. In the United States, it is available only through a Risk Evaluation and Mitigation Strategy (REMS) program, requiring administration in a certified healthcare setting and patient monitoring [2].
Can generic esketamine nasal spray be developed before patent expiry?
The development of generic versions of esketamine nasal spray is dependent on the expiration of relevant patents and the successful navigation of regulatory pathways, including the REMS program [3][5]. Challenges to patents can impact the timeline for generic market entry [3].